$ATR News

Earnings Preview: AptarGroup (ATR) Q3 Earnings Expected to Decline

Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers

AptarGroup's Aptar Pharma Reveals CE Marking For LuerVax

UBS Initiates Coverage On AptarGroup with Neutral Rating, Announces Price Target of $135

AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AptarGroup's Bottom Line Pressures Are Preventing An Upgrade

AptarGroup (ATR) Could Be 20% Undervalued On MGH Research Partnership

AptarGroup’s Russian Subsidiary Placed Under Temporary External Administration By Kremlin Decree; Says Aptar Vladimir Represented Less Than 0.6% Of Net Sales And Operating Income As Of Dec 31, 2025

AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

Aptar Collaborates With Massachusetts General Hospital To Advance Nose-To-Brain Drug Delivery And Accelerate CNS Pipelines

AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Why AptarGroup (ATR) International Revenue Trends Deserve Your Attention

Wells Fargo Maintains Overweight on AptarGroup, Raises Price Target to $155

AptarGroup Inc (ATR) (Q2 2026) Earnings Call Highlights: Record Sales and Strategic Wins Amid ...

AptarGroup Q2 Earnings Call Highlights

AptarGroup, Inc. (ATR) Q2 2026 Earnings Call Transcript

AptarGroup, Inc. Q2 2026 Earnings Call Summary

AptarGroup, Inc. 2026 Q2 - Results - Earnings Call Presentation

AptarGroup (ATR) Tops Q2 Earnings and Revenue Estimates